DECLARATION UNDER SUBSECTION 196B(9)

OF THE VETERANS’ ENTITLEMENTS ACT 1986

The Repatriation Medical Authority (the Authority), under subsection 196B(9) of the Veterans’ Entitlements Act 1986 (the Act), makes the following declaration in respect of the review of the contents of the Statements of Principles in force under the Act concerning acute myeloid leukaemia, Instrument Nos. 71 and 72 of 2015.

The investigation related to "insecticides". The Notice of Investigation was published in the Government Notices Gazette of 29 October 2019.

Following the investigation, the Authority declares that it does not propose to amend Statement of Principles, Instrument No. 72 of 2015, to include factors relating to exposure to insecticides. The reason is that the sound medical-scientific evidence available to the Authority, including the new sound medical-scientific evidence, cannot, on the balance of probabilities, connect acute myeloid leukaemia with exposure to insecticides related to the circumstances of the relevant service referred to in subsection 196B(3) of the Act. That sound medical-scientific evidence is not sufficient to justify an amendment to the Statement of Principles, No. 72 of 2015, already determined in respect of acute myeloid leukaemia, to include factors relating to exposure to insecticides.

The Authority proposes to determine an amendment to Statement of Principles, Instrument No. 71 of 2015, concerning acute myeloid leukaemia, to include factors relating to exposure to the insecticides dieldrin, aldrin and diazinon. The Authority is of the view that the sound medical-scientific evidence available to it, including the new sound medical-scientific evidence, raises a reasonable hypothesis connecting acute myeloid leukaemia with exposure to dieldrin, aldrin and diazinon related to the circumstances of relevant service referred to in subsection 196B(2) of the Act. That sound medical-scientific evidence justifies an amendment of the Statement of Principles, Instrument No. 71 of 2015, concerning acute myeloid leukaemia, to include factors relating to exposure to dieldrin, aldrin and diazinon.

The Common Seal of the Repatriation Medical Authority was affixed at the direction of:

PROFESSOR NICHOLAS SAUNDERS AO
CHAIRPERSON 28 / 2 / 2020

The Repatriation Medical Authority
GPO Box 1014, Brisbane, Qld 4001
Telephone: (07) 3815 9404 Email: info@rma.gov.au